You are here

Shingrix

Pfizer begins plan to challenge Shingrix with an mRNA vaccine

Pfizer begins plan to challenge Shingrix with an mRNA vaccine

BioPharma Dive

Flag link:

After Haleon spinoff, GSK raises forecasts on ‘strong’ Q3

After Haleon spinoff, GSK raises forecasts on ‘strong’ Q3

Pharmaphorum

Flag link:

GSK’s Shingrix showed to offer ten years of shingles protection in study

GSK’s Shingrix showed to offer ten years of shingles protection in study

Clinical Trials Arena

clinical trials

Flag link:

GSK ups sales guidance on back of Shingrix strength

GSK ups sales guidance on back of Shingrix strength

Biopharma Reporter

consumer health

Flag link:

GSK beats forecasts, thanks to COVID antibody and Shingrix sales

GSK beats forecasts, thanks to COVID antibody and Shingrix sales

Pharmaforum

Flag link:

Vaccines upstart Curevo has designs on blockbuster GSK franchise

Vaccines upstart Curevo has designs on blockbuster GSK franchise

Pharmaforum

Flag link:

A small Seattle biotech wants to take on GlaxoSmithKline's emerging Shingrix blockbuster. RA Capital is on board

A small Seattle biotech wants to take on GlaxoSmithKline's emerging Shingrix blockbuster. RA Capital is on board

Endpoints

Flag link:

As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine's reach

As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine's reach

Fierce Pharma

Flag link:

GlaxoSmithKline plans to 'relaunch' Shingrix after the pandemic decimated sales

GlaxoSmithKline plans to 'relaunch' Shingrix after the pandemic decimated sales

Fierce Pharma

Flag link:

FDA adds Guillain-Barré syndrome warning to GlaxoSmithKline’s shingles vaccine

FDA adds Guillain-Barré syndrome warning to GlaxoSmithKline’s shingles vaccine

Endpoints

Guillain-Barré Syndrome

Flag link:

GSK's Shingrix supply recovers thanks to drop in vaccinations, uninterrupted production

GSK's Shingrix supply recovers thanks to drop in vaccinations, uninterrupted production

Fierce Pharma

Flag link:

JPM: Glaxo sees enormous Shingrix potential, but a supply gap still stands in the way

JPM: Glaxo sees enormous Shingrix potential, but a supply gap still stands in the way

Fierce Pharma

Flag link:

GlaxoSmithKline's Shingrix supply will vault upward, CEO says—in 2024, that is

GlaxoSmithKline's Shingrix supply will vault upward, CEO says—in 2024, that is

Fierce Pharma

Flag link:

GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle China

GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle China

Fierce Pharma

Flag link:

Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses

Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses

Yahoo/Zacks.com

Flag link:

GSK invests $100m to boost vaccine manufacturing at US facility

GSK invests $100m to boost vaccine manufacturing at US facility

Pharmaceutical Business Review

drug manufacturing

Flag link:

Sales of shingles vaccine boost profits at GSK

Sales of shingles vaccine boost profits at GSK

Yahoo/Reuters

Flag link:

Sen. Schumer curiously links Shingrix shortage to shutdown, but Glaxo says there's no connection

Sen. Schumer curiously links Shingrix shortage to shutdown, but Glaxo says there's no connection

Fierce Pharma

government shutdown

Flag link:

GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'

GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'

Fierce Pharma

Flag link:

7 drugs that raised eyebrows in Q3

7 drugs that raised eyebrows in Q3

Biopharma Dive

Clovis Oncology

Flag link:

Pages